Cerus (NASDAQ:CERS) Reaches New 12-Month High After Better-Than-Expected Earnings

Key Points

• 52‑week high after Q1 beat — Cerus shares jumped (as high as $3.15) after reporting EPS of -$0.01 vs. -$0.03 expected and revenue of $59.9M (vs. $55.7M), driving about a 40% intraday rally.
• Offsetting headwinds: management gave FY‑2026 guidance of $227.0M–$231.0M below consensus (~$233.9M), and insiders have sold roughly 1.19M shares in the last 90 days.
• Mixed analyst view — BTIG upgraded CERS to a Buy with a $4 price target, but overall sentiment is a consensus "Hold" with an average target around $4 and high institutional ownership (~78%).

Cerus Corporation (NASDAQ:CERS - Get Free Report) hit a new 52-week high during mid-day trading on Friday following a stronger than expected earnings report. The stock traded as high as $3.15 and last traded at $2.86, with a volume of 7017316 shares trading hands. The stock had previously closed at $2.03.

The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. The firm had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%.

Cerus News Roundup

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 results beat expectations — Cerus reported revenue of ~$59.9M (up ~22.6% YoY) and EPS of -$0.01, topping estimates and showing a sharply reduced net loss; operating cash flow was positive (~$6.2M) and cash on hand ~$27.9M. Those fundamentals are the primary reason the stock is trading higher. Quiver Quantitative: CERS Stock Rises on Q1 2026 Earnings
• Positive Sentiment: Analyst upgrade: BTIG Research moved CERS from "neutral" to "buy" with a $4.00 price target (roughly double current levels), which supports upside sentiment and may attract momentum buyers. Benzinga: BTIG Upgrade
• Neutral Sentiment: Earnings call / disclosure: Full Q1 earnings call transcript and press materials were released for investors to parse product, margin and commercial commentary — useful for sizing ongoing growth drivers but not new price catalysts by themselves. Seeking Alpha: Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY‑2026 revenue guidance was updated to $227.0M–$231.0M, below the consensus (~$233.9M). That guidance shortfall is a headwind and likely the main reason some investors are taking profits or re‑rating estimates. MarketBeat: FY2026 Guidance
• Negative Sentiment: Insider selling: multiple executives have sold shares in the past six months (no recent purchases reported), which can raise governance or conviction questions for some investors. Quiver Quantitative: Insider Activity

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CERS shares. Wall Street Zen downgraded shares of Cerus from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cerus in a research note on Wednesday, March 25th. TD Cowen reaffirmed a "buy" rating on shares of Cerus in a research note on Monday, January 12th. BTIG Research raised shares of Cerus from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research note on Friday. Finally, Zacks Research downgraded shares of Cerus from a "hold" rating to a "strong sell" rating in a research note on Thursday, March 12th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $4.00.

Insider Buying and Selling at Cerus

In other Cerus news, CFO Kevin Dennis Green sold 127,544 shares of the firm's stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total transaction of $211,723.04. Following the completion of the transaction, the chief financial officer owned 1,040,551 shares of the company's stock, valued at approximately $1,727,314.66. This trade represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO William Mariner Greenman sold 447,757 shares of the firm's stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total transaction of $743,276.62. Following the transaction, the chief executive officer directly owned 4,998,493 shares of the company's stock, valued at $8,297,498.38. This represents a 8.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,194,282 shares of company stock valued at $2,106,290. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cerus

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of Cerus by 0.6% during the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company's stock valued at $17,147,000 after purchasing an additional 62,663 shares in the last quarter. Wasatch Advisors LP increased its stake in shares of Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company's stock valued at $12,033,000 after purchasing an additional 213,917 shares in the last quarter. Millennium Management LLC increased its stake in shares of Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company's stock valued at $5,517,000 after purchasing an additional 519,301 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Cerus by 1.1% during the fourth quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company's stock valued at $4,993,000 after purchasing an additional 25,771 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Cerus by 5.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,676,279 shares of the biotechnology company's stock valued at $3,453,000 after purchasing an additional 92,577 shares in the last quarter. Institutional investors own 78.37% of the company's stock.

Cerus Stock Up 40.1%

The stock's 50 day simple moving average is $1.97 and its two-hundred day simple moving average is $1.98. The firm has a market cap of $570.05 million, a P/E ratio of -35.19 and a beta of 1.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.